drugset
drugset / Trial / NCT05097053

A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

NCT05097053 ↗

Phase 4 Unknown 200 enrolled Taoyuan General Hospital Medigen Vaccine Biologics Corp. · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titers in adult participants in order to demonstrate the immunogenicity and safety of heterologous third-boost with MVC-COV1901, in terms of the neutralizing antibody GMTs at 28 days after the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity by the antigen-specific immunoglobulin as well as the potential efficacy of study intervention in preventing COVID-19. This study is aimed to recruit participants at single study site in Northern Taiwan.

Timeline

Start
2021-10-07
Primary completion
2022-03
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MVC-COV1901 Vaccine — —

Indications

No indication recorded.